Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, August 01, 2018
BridgeHealth now adds the North American Specialty Hospital in Cancun to its program of providers available to self-insured plan sponsors.
read more
Bright Green Corporation (BGXX) announced it will install a 102-megawatt solar field to power the electricity and heating requirements for the new $250 million Dalsem expansion project and commits to switch the existing facility that currently burns ...
read more
BrightInsight announced a global digital health partnership with AstraZeneca.
read more
BrightInsight and CSL Behring announced a global digital health partnership to provide digitally-enhanced treatment experiences and regulated digital health offerings to support CSL Behring therapies.
read more
The Food and Drug Administration said Thursday that some doctors and pharmacies are getting confused by the similar names of an antidepressant and a blood-thinning medicine.
read more
Bristol-Myers said Tuesday that federal regulators will help speed up development for one of its experimental HIV drugs.
read more
Bristol-Myers Squibb Company and Nordic Bioscience has announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis.
read more
Wednesday, November 04, 2015
Bristol-Myers Squibb has entered into a collaboration agreement with The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.
read more
Monday, September 09, 2019
PhRMA announced Giovanni Caforio, M.D., chairman and CEO of Bristol-Myers Squibb has assumed the role of chairman of the PhRMA board of directors.
read more
TARGET PharmaSolutions announced Bristol-Myers Squibb (BMY) has extended its strategic partnership for TARGET-NASH to a multi-year agreement.
read more
Bristol-Myers Squibb and Flatiron Health have expanded their relationship by announcing a three-year collaboration agreement.
read more
Thursday, February 15, 2018
Bristol-Myers Squibb and Nektar announced the companies have executed a global strategic development and commercialization collaboration for Nektar’s immuno-oncology program, NKTR-214.
read more
Bristol-Myers Squibb and QIAGEN signed an agreement to explore the use of NGS technology to develop GEPs as predictive or prognostic tools for use with Bristol-Myers Squibb novel I-O therapies in cancer treatment.
read more
Wednesday, September 16, 2015
Bristol-Myers Squibb Company has announced that the FDA has granted Breakthrough Therapy Designation to Opdivo for the potential indication of advanced or metastatic renal cell carcinoma (RCC).
read more
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive...
read more